To improve our knowledge of genetic diseases and rapidly evaluate new diagnostic and therapeutic avenues resulting from these discoveries, MMG scientists share their expertise and experience with leaders in research, clinical and industry and work closely with patient associations. With the support of SATT Sud Est, Inserm Transfert and Protisvalor, the research development subsidiaries of Inserm and Aix-Marseille University, it is actively pursuing a policy of patents, licensing and technology transfer.

In rare diseases, even more so than in other areas of research, partnerships are at the heart of the strategy. MMG scientists and clinicians conduct numerous collaborations with academic laboratories, healthcare units, industrialists and patient associations in France and abroad. In the same vein, he is also one of the founding members of MaRCHE, the university hospital federation dedicated to rare diseases, which is accredited by the A*MIDEX University Foundation, the AP-HM and the Alliance des Sciences de la Vie et de la Santé. These collaborations aim to:  

• Accelerate discovery by sharing skills, know-how and talents.
• Facilitate access to breakthrough technologies, innovative models or drugs already on the market.
• Reduce the diagnosis wandering of patients and their families.
• Maximize the impact of clinical trials (including patients, methodology, funding, etc.).
• Share with the greatest number of people the advances in rare diseases and their impact on much more frequent pathologies: cancer, osteoporosis, diabetes...

Valorization is also an essential component of the MMG strategy. It now has a solid portfolio of patents and licenses that cover innovative database systems with new diagnostic and therapeutic targets. The MMG's work has also led to the creation of ProGeLife, a spin-off that is now developing a first-in-class drug candidate for skin cancer, the main complication of patients with Xeroderma Pigmentosum.